Haemonetics Corp. Hits New 52-Week High at $92.12, Reflecting Strong Growth

Haemonetics Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 92.12 on August 13, 2026. This achievement underscores the company's recent performance, which has seen a 1-year increase of 5.28%, although it lags behind the S&P 500's performance of 20.6% during the same period. With a market capitalization of USD 2,511 million, Haemonetics Corp. operates with a price-to-earnings (P/E) ratio of 14.00, indicating its valuation relative to earnings. The company maintains a debt-to-equity ratio of 0.95, reflecting a balanced approach to leveraging. Additionally, Haemonetics boasts a return on equity of 19.13%, showcasing its efficiency in generating profits from shareholders' equity. Despite a dividend yield of 0.00%, the stock's performance metrics, including a price-to-book ratio of 2.76, highlight its position within the industry. The stock's previous 52-week low was recorded at USD 47.32, marking a notable recovery to its current high.